LifeMine revives frozen fungus platform with $188M Series E from Gates and Bezos
What's the deal? LifeMine Therapeutics has raised a $188 million Series E round, with backing from Bill GatesDealroom has a profile for this one. Try Dealroom → and Jeff BezosDealroom has a profile for this one. Try Dealroom →. The Massachusetts biotech mines fungi for new drug candidates.
Why now? In 2025, LifeMine laid off staff and put its fungus-based platform on ice, redirecting dwindling resources to its lead asset. The fresh capital lets it thaw that platform and restart broader research.
What's the endgame? LifeMine builds drug candidates by screening the chemistry produced by fungi. Reviving the platform reopens a pipeline the company had shelved to survive.
What could go wrong? The company was forced to freeze the same platform it is now restarting, a reminder of how quickly biotech resources can run dry. Star-name backers raise expectations but do not guarantee clinical results.
The signal: At $188 million, the round sits in the 95th percentile of US health Series E deals over the past four years, based on 64 comparable rounds. In a cautious biotech market, marquee investors are still willing to write large cheques for platforms with a credible second act.
Read more: Fierce Biotech
Image credit: Generated with Gemini
